Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

NCT03500094 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: Migalastat HCl 150 mg

Sponsor

Amicus Therapeutics